Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 72Thoracic 3Gynecologic 3Sarcoma 1Head & Neck 1

Conditions

Uterine Cervical Neoplasms 182Ovarian Neoplasms 92Carcinoma, Ovarian Epithelial 46Fallopian Tube Neoplasms 35Endometrial Neoplasms 29Peritoneal Neoplasms 23Stomach Neoplasms 18Colorectal Neoplasms 13Carcinoma, Non-Small-Cell Lung 13Neoplasms 11Vulvar Neoplasms 9Recurrence 9Lung Neoplasms 8Squamous Cell Carcinoma of Head and Neck 7Pancreatic Neoplasms 7Locally Advanced Cervical Cancer 7Brenner Tumor 7Uterine Neoplasms 6Testicular Neoplasms 6Parkinson Disease 4, Autosomal Dominant Lewy Body 6Neoplasm Metastasis 6Carcinoma 6Urinary Bladder Neoplasms 5Sarcoma 5Colonic Neoplasms 5Breast Neoplasms 5Vaginal Neoplasms 4Triple Negative Breast Neoplasms 4Teratoma 4Small Cell Lung Carcinoma 4

Interventions

pembrolizumab 6Nivolumab 3Cisplatin 3Carboplatin 3Paclitaxel 2Fluorouracil 2tucatinib 1pertuzumab 1milademetan 1lenvatinib 1cemiplimab 1Trastuzumab 1Tomography, X-Ray Computed 1Ritonavir 1Radiation 1Prednisone 1Prednisolone 1Positron-Emission Tomography 1Pemetrexed 1Oxaliplatin 1Magnetic Resonance Imaging 1Leucovorin 1Itraconazole 1Gemcitabine 1Fulvestrant 1Cetuximab 1Capecitabine 1Brachytherapy 1Bevacizumab 1AZD9833 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Biliary Tract Neoplasms × Cisplatin × Gynecologic × Clear all
NCT04956640 2026-05-29

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

Eli Lilly and Company

Phase 1/2 Active not recruiting
540 enrolled
GastrointestinalGynecologicThoracic

Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT05489211 2026-03-19

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

AstraZeneca

Phase 2 Recruiting
454 enrolled
GastrointestinalGynecologic

Biliary Tract Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT03314935 2025-08-12

A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors

Incyte Corporation

Phase 1/2 Completed
149 enrolled 35 charts
GastrointestinalGynecologic

Biliary Tract Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡